FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307728974> ?p ?o ?g. }

• W4307728974 endingPage "1596" @default.
• W4307728974 startingPage "1585" @default.
• W4307728974 abstract "The optimum systolic blood pressure after endovascular thrombectomy for acute ischaemic stroke is uncertain. We aimed to compare the safety and efficacy of blood pressure lowering treatment according to more intensive versus less intensive treatment targets in patients with elevated blood pressure after reperfusion with endovascular treatment.We conducted an open-label, blinded-endpoint, randomised controlled trial at 44 tertiary-level hospitals in China. Eligible patients (aged ≥18 years) had persistently elevated systolic blood pressure (≥140 mm Hg for >10 min) following successful reperfusion with endovascular thrombectomy for acute ischaemic stroke from any intracranial large-vessel occlusion. Patients were randomly assigned (1:1, by a central, web-based program with a minimisation algorithm) to more intensive treatment (systolic blood pressure target <120 mm Hg) or less intensive treatment (target 140-180 mm Hg) to be achieved within 1 h and sustained for 72 h. The primary efficacy outcome was functional recovery, assessed according to the distribution in scores on the modified Rankin scale (range 0 [no symptoms] to 6 [death]) at 90 days. Analyses were done according to the modified intention-to-treat principle. Efficacy analyses were performed with proportional odds logistic regression with adjustment for treatment allocation as a fixed effect, site as a random effect, and baseline prognostic factors, and included all randomly assigned patients who provided consent and had available data for the primary outcome. The safety analysis included all randomly assigned patients. The treatment effects were expressed as odds ratios (ORs). This trial is registered at ClinicalTrials.gov, NCT04140110, and the Chinese Clinical Trial Registry, 1900027785; recruitment has stopped at all participating centres.Between July 20, 2020, and March 7, 2022, 821 patients were randomly assigned. The trial was stopped after review of the outcome data on June 22, 2022, due to persistent efficacy and safety concerns. 407 participants were assigned to the more intensive treatment group and 409 to the less intensive treatment group, of whom 404 patients in the more intensive treatment group and 406 patients in the less intensive treatment group had primary outcome data available. The likelihood of poor functional outcome was greater in the more intensive treatment group than the less intensive treatment group (common OR 1·37 [95% CI 1·07-1·76]). Compared with the less intensive treatment group, the more intensive treatment group had more early neurological deterioration (common OR 1·53 [95% 1·18-1·97]) and major disability at 90 days (OR 2·07 [95% CI 1·47-2·93]) but there were no significant differences in symptomatic intracerebral haemorrhage. There were no significant differences in serious adverse events or mortality between groups.Intensive control of systolic blood pressure to lower than 120 mm Hg should be avoided to prevent compromising the functional recovery of patients who have received endovascular thrombectomy for acute ischaemic stroke due to intracranial large-vessel occlusion.The Shanghai Hospital Development Center; National Health and Medical Research Council of Australia; Medical Research Futures Fund of Australia; China Stroke Prevention; Shanghai Changhai Hospital, Science and Technology Commission of Shanghai Municipality; Takeda China; Hasten Biopharmaceutic; Genesis Medtech; Penumbra." @default.
• W4307728974 created "2022-11-05" @default.
• W4307728974 creator A5001525877 @default.
• W4307728974 creator A5001916762 @default.
• W4307728974 creator A5005538880 @default.
• W4307728974 creator A5006342059 @default.
• W4307728974 creator A5008807851 @default.
• W4307728974 creator A5009830533 @default.
• W4307728974 creator A5010333333 @default.
• W4307728974 creator A5010546148 @default.
• W4307728974 creator A5011046660 @default.
• W4307728974 creator A5011477215 @default.
• W4307728974 creator A5011543847 @default.
• W4307728974 creator A5015718651 @default.
• W4307728974 creator A5015971780 @default.
• W4307728974 creator A5016138743 @default.
• W4307728974 creator A5017422746 @default.
• W4307728974 creator A5022820465 @default.
• W4307728974 creator A5026053703 @default.
• W4307728974 creator A5028505860 @default.
• W4307728974 creator A5029834788 @default.
• W4307728974 creator A5033108882 @default.
• W4307728974 creator A5034911893 @default.
• W4307728974 creator A5035593861 @default.
• W4307728974 creator A5036724817 @default.
• W4307728974 creator A5038427797 @default.
• W4307728974 creator A5039199933 @default.
• W4307728974 creator A5047591121 @default.
• W4307728974 creator A5048985261 @default.
• W4307728974 creator A5049798132 @default.
• W4307728974 creator A5053320375 @default.
• W4307728974 creator A5054651477 @default.
• W4307728974 creator A5055151897 @default.
• W4307728974 creator A5057751824 @default.
• W4307728974 creator A5060766325 @default.
• W4307728974 creator A5060985903 @default.
• W4307728974 creator A5062088250 @default.
• W4307728974 creator A5062097440 @default.
• W4307728974 creator A5063975444 @default.
• W4307728974 creator A5064710618 @default.
• W4307728974 creator A5065534299 @default.
• W4307728974 creator A5065999911 @default.
• W4307728974 creator A5066287913 @default.
• W4307728974 creator A5066883553 @default.
• W4307728974 creator A5069603301 @default.
• W4307728974 creator A5069721762 @default.
• W4307728974 creator A5070046055 @default.
• W4307728974 creator A5071437310 @default.
• W4307728974 creator A5073071897 @default.
• W4307728974 creator A5073606624 @default.
• W4307728974 creator A5074508324 @default.
• W4307728974 creator A5074882599 @default.
• W4307728974 creator A5077695586 @default.
• W4307728974 creator A5078329914 @default.
• W4307728974 creator A5080100010 @default.
• W4307728974 creator A5081284579 @default.
• W4307728974 creator A5081536114 @default.
• W4307728974 creator A5081542140 @default.
• W4307728974 creator A5082889999 @default.
• W4307728974 creator A5083080398 @default.
• W4307728974 creator A5084412014 @default.
• W4307728974 creator A5084685500 @default.
• W4307728974 creator A5085225196 @default.
• W4307728974 creator A5087550907 @default.
• W4307728974 date "2022-11-01" @default.
• W4307728974 modified "2023-10-10" @default.
• W4307728974 title "Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial" @default.
• W4307728974 cites W2003188614 @default.
• W4307728974 cites W2117855158 @default.
• W4307728974 cites W2254662803 @default.
• W4307728974 cites W2277258071 @default.
• W4307728974 cites W2344655128 @default.
• W4307728974 cites W2606371730 @default.
• W4307728974 cites W2621274857 @default.
• W4307728974 cites W2804890047 @default.
• W4307728974 cites W2890223142 @default.
• W4307728974 cites W2891019753 @default.
• W4307728974 cites W2911196419 @default.
• W4307728974 cites W2914098214 @default.
• W4307728974 cites W2917585458 @default.
• W4307728974 cites W2963274253 @default.
• W4307728974 cites W2994967021 @default.
• W4307728974 cites W2998957896 @default.
• W4307728974 cites W3023339300 @default.
• W4307728974 cites W3123951518 @default.
• W4307728974 cites W3130560030 @default.
• W4307728974 cites W3133993978 @default.
• W4307728974 cites W3179604039 @default.
• W4307728974 cites W3193653141 @default.
• W4307728974 cites W3201556233 @default.
• W4307728974 cites W3206422306 @default.
• W4307728974 cites W3214305484 @default.
• W4307728974 cites W4211186001 @default.
• W4307728974 cites W4226129296 @default.
• W4307728974 cites W4226325860 @default.
• W4307728974 cites W4290793057 @default.
• W4307728974 doi "https://doi.org/10.1016/s0140-6736(22)01882-7" @default.
• W4307728974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36341753" @default.

• next